Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MEDI8897

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

AstraZeneca AZ

AZ’s COPD triple data sets up market clash with GSK

KRONOS trial showed significant improvements in lung function tests over two-drug combos

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy picks up another indication in Europe

The EC licenses the immuno-oncology treatment for children with skin cancer

- PMLiVE

MHRA: No change for pre-Brexit products after UK exits the EU

And UK plans to follow EU rules for an implementation period after March 2019

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

AstraZeneca AZ

AZ pushes harder into China with new joint venture

The Anglo-Swedish group creates a new pharmaceutical business with the Chinese FIIF

AstraZeneca AZ

AZ prices severe asthma drug Fasenra below competition

The discounted drug will cost $38,000 in the first year

AstraZeneca AZ

AZ severe asthma drug benralizumab backed by CHMP

The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma

- PMLiVE

Porterhouse Medical expands into the US

UK med comms group opens new subsidiary in Philadelphia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links